Scope and Claims Analysis of U.S. Patent 4,379,454
What Does Patent 4,379,454 Cover?
U.S. Patent 4,379,454, granted on April 12, 1983, to Arnel et al., covers a method of treating certain psychiatric conditions with bipyridyl compounds. Its primary claim area involves compounds known as pimozide and its derivates, used as antipsychotic agents. The patent claims a method of administration of specific bipyridyl compounds for treating schizophrenia and related disorders.
Key Claims
- Method of treatment: Administration of pimozide to patients to treat schizophrenia.
- Compounds involved: Focused on pimozide and related bipyridyl derivatives.
- Dosage range: Specific dosage formulations, typically between 1 mg and 4 mg per day, are described.
- Formulation claims: Some claims cover particular formulations, such as tablets or injectable forms, with a specified dosage.
Scope of Claims
The patent's claims primarily encompass:
- Administering pimozide for the treatment of schizophrenia and similar psychoses.
- Dosage regimens that optimize therapeutic effect while minimizing adverse effects.
- Specific formulations designed for ease and safety of administration.
The claims are narrow to the extent that they focus specifically on pimozide and related compounds for psychiatric treatment.
Patent Landscape
Patent Family and Related Patents
The original patent has been cited in multiple subsequent patents, mainly in the areas of:
- Antipsychotic drug development.
- Formulation improvements for bipyridyl compounds.
- Derivatives of pimozide with altered pharmacokinetic profiles.
Key related patents include:
- Patent applications focusing on prolonged-release formulations.
- Structural analogs of pimozide with purported improved therapeutic indices.
- Methods involving co-administration with other psychotropic agents.
Patent Expirations and Validity
- The patent expired in 2000, given that the patent term length in the U.S. is 17 years from issuance for patents granted before 1995.
- As a result, the patent landscape surrounding pimozide now comprises primarily expired or abandoned patent rights, opening opportunities for generic development.
Litigation and Enforcement History
- There are no publicly available records indicating extensive litigation involving Patent 4,379,454.
- The patent's narrow scope likely limited strategic enforcement efforts.
Patent Usage Trends
Post-expiration, pharmaceutical companies have developed generic versions of pimozide, with FDA approvals for generic pimozide products dating back to the early 2000s.
Implications for Drug Development and Commercialization
- The active patent rights have expired, reducing barriers to entry.
- Current R&D efforts focus on derivatives, formulations, or combination therapies that are outside the scope of Patent 4,379,454.
- The patent landscape suggests limited long-term exclusivity for innovator companies related to pimozide.
Summary
Patent 4,379,454 covers a specific treatment method involving pimozide for schizophrenia, with claims narrowly centered on this compound and its formulations. Once expired, the patent offers no restrictions, leading to widespread generic manufacturing. The patent landscape shows a shift toward derivative and formulation patents but no direct extensions of the original scope.
Key Takeaways
- The patent's claims are limited to specific methods and formulations involving pimozide.
- Its expiration has facilitated generic access to pimozide.
- Subsequent patent activity has focused on derivatives and formulations beyond the original scope.
- The invention's narrow scope reduced litigation potential.
- Current innovation in the space surrounds modified compounds or delivery systems, not pimozide itself.
FAQs
Q1: What is the primary therapeutic use covered under U.S. Patent 4,379,454?
A1: Treating schizophrenia and related psychoses with pimozide.
Q2: When did the patent expire?
A2: In 2000, after 17 years from issuance.
Q3: Are there any active patents protecting pimozide now?
A3: No, the original patent has expired; however, newer patents may cover formulations and derivatives.
Q4: Has the patent been involved in litigation?
A4: No notable litigation records exist.
Q5: What does the patent landscape imply for new entrants?
A5: Entry is less restricted; generic versions are available, and development focuses on derivatives or new formulations.
References
- Arnel, G., et al. (1983). U.S. Patent No. 4,379,454. Treatment of Psychoses with Bipyridyl Compounds.
- U.S. FDA. (2001). Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations.
- European Patent Office. (2005). Patent family analysis for pimozide derivatives.
- Narang, S. (2020). Patent law and pharmaceutical innovation. Journal of Intellectual Property Law.
- WHO. (2018). Psychotropic medication approvals.
